Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-08, Vol.190 (4), p.e258-e261
Hauptverfasser:	Menter, Thomas, Hayoz, Stefanie, Zucca, Emanuele, Kimby, Eva, Dirnhofer, Stefan, Tzankov, Alexandar
Format:	Artikel
Sprache:	eng
Schlagworte:	CD4-CD8 Ratio follicular lymphoma Gene Expression Profiling Helper cells Hematology Humans Immunologic Factors - administration & dosage Immunomodulation Kaplan-Meier Estimate lenalidomide Lenalidomide - administration & dosage Lymphocytes T Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - genetics Lymphoma, Follicular - mortality Medicin och hälsovetenskap Neoplasm Proteins - biosynthesis Neoplasm Proteins - genetics Prognosis Progression-Free Survival Randomized Controlled Trials as Topic - statistics & numerical data Rituximab - administration & dosage RORγt Th17 Cells - immunology Th17 T cells Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!